Heparin-induced thrombocytopenia (HIT) is an immunologic drug reaction characterized by the presence of heparin-induced antibodies against heparin-platelets factor4(PF4) complex, thrombocytopenia, and paradoxical thrombosis. Little information is available on the persistence of heparin/PF4 antibody complexes in the plasma.The aim of this study was to evaluate the time course of heparin/PF4 antibodies in patients (pts) exposed to heparin. We enrolled 500 pts treated with i.v. heparin as part of perioperative management of CABG, 131 of them developed serologically confirmed heparin/PF4 antibodies, and were then selected and followed-up. Serum concentration of circulating heparin-induced antibodies was repeatedly assessed over a period of 3 years by an ELISA immunoassay; we also evaluated occurrence of thrombotic events during follow-up. 131 of 500 pts (26.2%) developed anti-PF4/heparin antibodies which persisted for 90 days (median time 95%CI 80 to 156). Baseline platelet count did not differ between the antibody-positive and -negative groups, in contrast the nadir platelet count was significantly lower in antibody-positive pts (85.000 ± 21.000 vs 141.000 ± 41.000, p < 0.001).

Heparin/PF4 Antibodies Formation after Heparin Treatment: Temporal Aspects and Long-Term Follow-Up / Mattioli, Anna Vittoria; Lorenzo, Bonetti; Mauro, Zennaro; Ines, Castellana; Giuseppe, Ambrosio; Mattioli, Giorgio. - In: CIRCULATION. - ISSN 0009-7322. - STAMPA. - 118:(2008), pp. S364-S364. (Intervento presentato al convegno American Heart Association Scientific Session tenutosi a New Orleans USA nel 8-12 Novembre 2008).

Heparin/PF4 Antibodies Formation after Heparin Treatment: Temporal Aspects and Long-Term Follow-Up

MATTIOLI, Anna Vittoria;MATTIOLI, Giorgio
2008

Abstract

Heparin-induced thrombocytopenia (HIT) is an immunologic drug reaction characterized by the presence of heparin-induced antibodies against heparin-platelets factor4(PF4) complex, thrombocytopenia, and paradoxical thrombosis. Little information is available on the persistence of heparin/PF4 antibody complexes in the plasma.The aim of this study was to evaluate the time course of heparin/PF4 antibodies in patients (pts) exposed to heparin. We enrolled 500 pts treated with i.v. heparin as part of perioperative management of CABG, 131 of them developed serologically confirmed heparin/PF4 antibodies, and were then selected and followed-up. Serum concentration of circulating heparin-induced antibodies was repeatedly assessed over a period of 3 years by an ELISA immunoassay; we also evaluated occurrence of thrombotic events during follow-up. 131 of 500 pts (26.2%) developed anti-PF4/heparin antibodies which persisted for 90 days (median time 95%CI 80 to 156). Baseline platelet count did not differ between the antibody-positive and -negative groups, in contrast the nadir platelet count was significantly lower in antibody-positive pts (85.000 ± 21.000 vs 141.000 ± 41.000, p < 0.001).
2008
118
S364
S364
Mattioli, Anna Vittoria; Lorenzo, Bonetti; Mauro, Zennaro; Ines, Castellana; Giuseppe, Ambrosio; Mattioli, Giorgio
Heparin/PF4 Antibodies Formation after Heparin Treatment: Temporal Aspects and Long-Term Follow-Up / Mattioli, Anna Vittoria; Lorenzo, Bonetti; Mauro, Zennaro; Ines, Castellana; Giuseppe, Ambrosio; Mattioli, Giorgio. - In: CIRCULATION. - ISSN 0009-7322. - STAMPA. - 118:(2008), pp. S364-S364. (Intervento presentato al convegno American Heart Association Scientific Session tenutosi a New Orleans USA nel 8-12 Novembre 2008).
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/637761
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 0
social impact